With Two New Deals, Versant Ventures Enlists More Pharma Partners To Share Biotech Risk
This article was originally published in The Pink Sheet Daily
Versant is betting a sizable amount of its portfolio on drug assets, instead of full-blown companies, with single buyers holding options to acquire each one.
You may also be interested in...
Versant Ventures is backing Inception Sciences, a new company led by former Amira chief scientist Peppi Prasit that aims to spin out multiple programs into separate companies, a new model gaining traction in the biotech world.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.